CRN04777
Congenital Hyperinsulinism
Phase 2Active (SUNRISE)
Key Facts
Indication
Congenital Hyperinsulinism
Phase
Phase 2
Status
Active (SUNRISE)
Company
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.
View full company profileTherapeutic Areas
Other Congenital Hyperinsulinism Drugs
| Drug | Company | Phase |
|---|---|---|
| Zegalogue (dasiglucagon) | Zealand Pharma | Approved |